# Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-and-safety-of-ly3298176-a-novel-dual-gip-and-glp-1-receptor-agonist-in/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Juan P. Frías,Michael A. Nauck,Joanna Van,Mark E Kutner,Xuewei Cui,Charles Benson,Shweta Urva,Ruth E. Gimeno,Zvonko Miličević,Deborah A. Robins,Axel Haupt |
| Citations | 810 |
| DOI | 10.1016/s0140-6736(18)32260-8 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2895666357 |
| PMID | 30293770 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Axel Haupt](https://scholariq.org/researchers/axel-haupt/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Hyperglycemia and glycemic control in critically ill and hospitalized patients](https://scholariq.org/topics/hyperglycemia-and-glycemic-control-in-critically-ill-and-hospitalized-patients/)
- [Bariatric Surgery and Outcomes](https://scholariq.org/topics/bariatric-surgery-and-outcomes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.